Los Angeles Capital Management
ABOS icon

Los Angeles Capital Management’s Acumen Pharmaceuticals ABOS Stock Holding History

Los Angeles Capital Management’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-56,592
Closed -$221K – 1307
2022
Q1 		$221K Buy
+56,592
New +$308K ﹤0.01% 1338

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
GPC
Guardian Point Capital Charlottesville, Virginia $243M AUM 22.43% 1-Year Est. Return

Los Angeles Capital Management's ABOS Position: Q2 2022 in Review

Los Angeles Capital Management sold out of Acumen Pharmaceuticals (ABOS) in Q2 2022, closing a stake of 56,592 shares — an estimated $221K sold.

Los Angeles Capital Management first reported a position in ABOS in Q1 2022 and held it in 1 quarter. The position peaked at $221K in Q1 2022. 47 funds tracked by Wall St. Rank hold ABOS as of Q2 2022.

  • Los Angeles Capital Management reported no remaining Acumen Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Los Angeles Capital Management sold 56,592 Acumen Pharmaceuticals shares in Q2 2022, an estimated $221K.
  • Los Angeles Capital Management first reported a position in Acumen Pharmaceuticals in Q1 2022 and held it in 1 quarter.
  • Los Angeles Capital Management's Acumen Pharmaceuticals position peaked at $221K in Q1 2022.
  • 47 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q2 2022.

Based on Los Angeles Capital Management's 13F filing for Q2 2022, filed 5 Aug 2022.